These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29171358)

  • 1. The comparative pharmacokinetics of physical manipulation by crushing of Xtampza
    Brennan MJ; Kopecky EA; Marseilles A; O'Connor M; Fleming AB
    Pain Manag; 2017 Nov; 7(6):461-472. PubMed ID: 29171358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
    Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
    Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza
    Gudin J
    J Opioid Manag; 2020; 16(2):127-139. PubMed ID: 32329888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Human Abuse Potential of Oxycodone DETERx
    Kopecky EA; Fleming AB; Levy-Cooperman N; O'Connor M; M Sellers E
    J Clin Pharmacol; 2017 Apr; 57(4):500-512. PubMed ID: 27669664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
    Meske D; Kopecky EA; Passik S; Shram MJ
    J Opioid Manag; 2018; 14(5):359-372. PubMed ID: 30387859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
    Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP
    J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
    Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR
    J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults.
    Perrino PJ; Colucci SV; Apseloff G; Harris SC
    Clin Drug Investig; 2013 Jun; 33(6):441-9. PubMed ID: 23677743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin.
    Olatoke O; Zah V; Stanicic F; Vukicevic D; Yfantopoulos P; Thompson C; DeGeorge MK; Passik S
    Clinicoecon Outcomes Res; 2022; 14():119-128. PubMed ID: 35264862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Drug Release After Crushing: Evaluation of Xtampza
    Mayock SP; Saim S; Fleming AB
    Clin Drug Investig; 2017 Dec; 37(12):1117-1124. PubMed ID: 28940174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
    Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
    Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.
    Harris SC; Perrino PJ; Smith I; Shram MJ; Colucci SV; Bartlett C; Sellers EM
    J Clin Pharmacol; 2014 Apr; 54(4):468-77. PubMed ID: 24243216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.
    Webster LR; Iverson M; Pantaleon C; Smith MD; Kinzler ER; Aigner S
    Pain Med; 2019 Apr; 20(4):747-757. PubMed ID: 29608768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse-deterrent properties of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
    Kucera SA; Zamloot MS; Crowley MM; Burns LH; Friedmann N; Barbier R
    J Opioid Manag; 2018; 14(6):429-436. PubMed ID: 30629279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
    Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
    J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER.
    Geoffrey Severtson S; Kreider SED; Amioka EC; Margolin ZR; Iwanicki JL; Dart RC
    Pain Med; 2020 Dec; 21(12):3660-3668. PubMed ID: 33094329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial.
    Morton T; Kostenbader K; Montgomery J; Devarakonda K; Barrett T; Webster L
    Postgrad Med; 2014 Jul; 126(4):20-32. PubMed ID: 25141240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
    Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
    Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.